The day at a glance · 3 min read
Mood · Cautious
+15
Sentiment, −100 to +100
Calytrix acquisition
$1.5bn
M&A & Corporate Strategy
Institutional share additions
1.3 million
M&A & Corporate Strategy
Extended dose
700 mg
FDA & Regulatory Approvals
Key driverM&A activity and regulatory approvals offset patent expiration headwinds for major pharmaceutical companies
Daily briefHealthcare· Money365.Market AI ·

Lilly Acquires Calytrix; Regeneron Wins EU Libtayo Approval

M&A activity and regulatory wins lead healthcare sector as Pfizer navigates patent cliff challenges.

M&A & Corporate Strategy

Bullish
01LLY
Eli Lilly (LLY) has agreed to acquire Calytrix Bio for $1.5bn, with shareholders set to receive an upfront payment followed by additional payouts contingent on reaching clinical and regulatory milestones. The deal attracted attention from institutional investors, with Susquehanna and Prudential adding 1.3 million shares in related holdings during the third quarter. Prudential's stake in companies potentially impacted by the transaction grew nearly 24-fold during the period.
02PFE
Pfizer (PFE) (common stock) has closed its acquisition of Metsera, marking a re-entry into the obesity drug market focused on injectables. The deal gives Pfizer control of Metsera's portfolio of long-acting obesity drug candidates targeting chronic weight management, with management planning to use the programs to compete in the crowded anti-obesity drug segment. At the Jefferies London Healthcare Conference, CEO Albert Bourla said the company expects recently launched medicines and a growing pipeline to help it emerge from a loss-of-exclusivity period with high single-digit growth, while also highlighting ambitions in monthly obesity drug formulations.

FDA & Regulatory Approvals

Bullish

Standard dose

350 mg

Reduced infusion time

15 minutesfrom 30 min
01REGN
Regeneron Pharmaceuticals (REGN) (common stock) announced that the European Commission has approved an extended dosing regimen of Libtayo (cemiplimab) at 700 mg given every six weeks, following an initial 12 weeks of treatment with Libtayo 350 mg every three weeks, across skin, lung and cervical cancer indications. The approval also includes an option to reduce subsequent infusion times of Libtayo 350 mg by up to half, from 30 minutes to 15 minutes, after a well-tolerated 30-minute infusion. The extended dosing and faster infusion approval applies across all current EU-approved oncology indications for the PD-1 inhibitor.

Biotech Pipeline & Access Initiatives

Neutral

Gilead analyst target

$130.69-22.2%

IBB Gilead purchase

$7.7 million

Moderna price

$215+736.3%
01GILD
Gilead Sciences (GILD) (common stock) announced royalty-free licensing deals for its investigational Ebola treatment obeldesivir in low and lower-middle-income countries, aiming to widen future access through local generic manufacturers if the antiviral gains regulatory authorization. The company also updated existing voluntary licenses for remdesivir to keep access in step with changing clinical and access needs. An analyst rated Gilead a Hold with a 12-month target of $130.69, implying 22.2% downside as shares trade at a premium to peers, while the iShares Biotechnology ETF added $7.7 million of Gilead shares on November 13 as part of $84.9 million in new buying across positions.
02MRNA▼ -3.63%
Moderna (MRNA) (common stock) traded at $215, with shares having returned 736.3% over the twelve months through mid-November compared to 11.7% for the S&P 500, as the healthcare stock hit multi-year highs amid positive results from its personalized cancer vaccine. Analysts examining the valuation concluded that at current levels the stock already prices in a comeback, raising questions about upside potential over the next five years.

Big Pharma Performance Comparison

Neutral
01JNJ
Johnson & Johnson (JNJ) (common stock) has seen its revenue climb quarter after quarter, while Novo Nordisk revenue has stayed largely flat apart from one notable jump, according to a comparative analysis of the two pharmaceutical giants' recent financial trajectories. The diverging revenue patterns highlight different growth dynamics between diversified healthcare conglomerates and specialty pharmaceutical companies focused on specific therapeutic areas.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy